share_log

諾輝健康：正面盈利警告

NH HEALTH: POSITIVE PROFIT ALERT

香港交易所 ·  Jan 22 03:51
Summary by Moomoo AI
諾輝健康於2024年1月22日發布正面盈利警告，預告截至2023年12月31日止年度的財務表現將顯著增長。根據未經審核的管理賬目初步審閱，公司預計年度收入總額將達到人民幣1,978.8百萬元至2,049.8百萬元，同比增長158.9%至168.2%；毛利預計將達到人民幣1,807.6百萬元至1,873.2百萬元，同比增長179.9%至190.0%。增長主要得益於公司旗下產品常衛清、幽幽管及噗噗管的銷售收入及毛利增加。其中，常衛清的銷售收入及毛利預計將分別增長230.6%至239.9%及263.8%至273.6%；幽幽管分別增長118.3%至127.5%及127.1%至136.8%；噗噗管分別增...展開全部
諾輝健康於2024年1月22日發布正面盈利警告，預告截至2023年12月31日止年度的財務表現將顯著增長。根據未經審核的管理賬目初步審閱，公司預計年度收入總額將達到人民幣1,978.8百萬元至2,049.8百萬元，同比增長158.9%至168.2%；毛利預計將達到人民幣1,807.6百萬元至1,873.2百萬元，同比增長179.9%至190.0%。增長主要得益於公司旗下產品常衛清、幽幽管及噗噗管的銷售收入及毛利增加。其中，常衛清的銷售收入及毛利預計將分別增長230.6%至239.9%及263.8%至273.6%；幽幽管分別增長118.3%至127.5%及127.1%至136.8%；噗噗管分別增長72.9%至82.4%及85.3%至96.4%。此外，公司的現金結餘及特定金融資產預計將從2022年的人民幣1,572.7百萬元增至人民幣1,819.0百萬元至1,821.0百萬元。諾輝健康強調，上述數據未經審核，且未經公司董事會審核委員會審核或審閱，僅供投資者參考，並提醒股東及潛在投資者勿完全依賴此資料作交易決策。
Novi Health issued a positive profit warning on January 22, 2024, and forecast a significant increase in its financial performance for the year ended December 31, 2023. Based on the preliminary review of unaudited management accounts, the Company expects total annual revenue to reach RMB1,978.8 million to RMB2,049.8 million, a year-on-year increase of 158.9% to 168.2%; gross profit is expected to reach RMB1,807.6 million to 1,873.2 million, a year-on-year increase of 179.9% to 190.0%. The growth was mainly driven by increased sales revenue and gross profit for the Company's products, Sanitary Ware, and Spook Tubes. Among them, the sales revenue and gross profit of Changwei Qing are expected to grow 230.6% to 239.9% and 263.8% to 273.6%, respectively, to grow by 118.3% to 127.5% and 127.1% to 136.8%, respectively, to grow by 72.9% to 82.4% and 85.3% to...Show More
Novi Health issued a positive profit warning on January 22, 2024, and forecast a significant increase in its financial performance for the year ended December 31, 2023. Based on the preliminary review of unaudited management accounts, the Company expects total annual revenue to reach RMB1,978.8 million to RMB2,049.8 million, a year-on-year increase of 158.9% to 168.2%; gross profit is expected to reach RMB1,807.6 million to 1,873.2 million, a year-on-year increase of 179.9% to 190.0%. The growth was mainly driven by increased sales revenue and gross profit for the Company's products, Sanitary Ware, and Spook Tubes. Among them, the sales revenue and gross profit of Changwei Qing are expected to grow 230.6% to 239.9% and 263.8% to 273.6%, respectively, to grow by 118.3% to 127.5% and 127.1% to 136.8%, respectively, to grow by 72.9% to 82.4% and 85.3% to 96.4%, respectively. In addition, the Company's cash balances and specific financial assets are expected to increase from RMB1,572.7 million in 2022 to RMB1,819.0 million to RMB1,821.0 million. Novi Health emphasizes that the above data is unaudited and has not been reviewed or reviewed by the Audit Committee of the Company's Board of Directors for investor reference only and reminds shareholders and potential investors not to rely entirely on this information for trading decisions.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more